EQS-News: CGM reports FY 2024 financials in line with revised guidance and expects to return to growth path in 2025
|
EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Annual Results/Annual Report
Koblenz - CompuGroup Medical, one of the world's leading e-health providers, recorded revenues of EUR 1,154.0 million in the 2024 financial year, 3 percent below the previous year's level (PY: EUR 1,187.7 million), which was attributable to high one-off effects in the previous year. Organically, revenues were 2 percent below the prior year. At EUR 300.1 million, one-time revenues were 20 percent below the prior year (PY: EUR 373.7 million). Recurring revenues increased by 5 percent to EUR 853.9 million (PY: EUR 814.0 million). The share of recurring revenues increased by 5 percentage points and now accounts for 74 percent of total revenues. In the same period, adjusted EBITDA declined by 15 percent to EUR 224.6 million (PY: EUR 264.8 million). The EBITDA margin stood at 19 percent (PY: 22 percent). Despite the decline in revenue, CGM continued to invest significantly in innovative products and solutions. Expenses for research and development rose year-on-year from EUR 252 million to EUR 255 million in 2024. In 2024, CompuGroup Medical once again demonstrated its innovative capabilities and its focus on advancing products and solutions. The initiative launched in 2023 to further expand the use of artificial intelligence (AI), machine learning and large language models within the group was consistently continued in 2024. Several CGM products and solutions already rely on AI-based functions, such as the CGM ONE telephone assistant for doctor's offices or CGM STELLA, the first cloud-based pharmacy software, also in combination with ASK STELLA, an AI-assisted module for pharmacy customers. Adjusted earnings per share amounted to EUR 1.27 in the financial year 2024 (PY: EUR 2.06). Free cash flow decreased by EUR 46.6 million to EUR 66.4 million compared to the prior year. Net debt amounted to EUR 772.8 million at the end of December 2024, compared to EUR 702.5 million at the end of December 2023. In the Ambulatory Information Systems (AIS) segment, revenues in 2024 amounted to EUR 693.6 million, 5 percent below the prior year’s figure of EUR 731.8 million. Recurring revenues increased to EUR 529.1 million (PY: EUR 513.0 million). The share of recurring revenues in segment revenues rose from 70 percent to 76 percent. Revenues in the Hospital Information Systems (HIS) segment grew by 1 percent to EUR 319.0 million in the financial year 2024 (PY: EUR 314.9 million). Recurring revenues increased by 9 percent to EUR 227.8 million (PY: EUR 209.7 million). The share of recurring revenues rose from 67 percent to 71 percent. In the Pharmacy Information Systems (PCS) segment, revenues in the 2024 financial year slightly increased to EUR 141.3 million (PY: EUR 141.0 million). Recurring revenues in the PCS segment increased by 6 percent to EUR 97.0 million (PY: EUR 91.3 million). The share of recurring revenues in segment revenues increased from 65 percent to 69 percent. CGM expects to return to the growth path in 2025, with organic revenue growth (adjusted for acquisitions and currency effects) in the low to mid-single digit percentage range year-on-year. Adjusted EBITDA is expected to show slight growth compared to 2024. All three operating segments are expected to achieve at least modest organic revenues growth. CompuGroup Medical SE & Co. KGaA (CGM) aims to hold its Annual General Meeting on August 01, this year. The general partner and the Supervisory Board propose a dividend of EUR 0.05 per share to the Annual General Meeting. The proposal comes against the backdrop of the company's long-term innovation and growth strategy, including investments in infrastructure and resources for greater customer centricity and AI-based processes and products. Based on the consolidated financial statements, it also takes into account the revenue and profitability development in the 2024 financial year in accordance with the revised guidance. The full year financial report 2024 is available for download at www.cgm.com/ir-publications.
06.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096184 |
| End of News | EQS News Service |
|
|
2096184 06.03.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 745,81 | 837,26 | 1.025,32 | 1.129,74 | 1.187,66 | 1.153,99 | 1.188,00 | |
| EBITDA1,2 | 178,13 | 197,48 | 213,39 | 216,35 | 229,76 | 218,74 | 0,00 | |
| EBITDA-Margin3 | 23,88 | 23,59 | 20,81 | 19,15 | 19,35 | 18,96 | 0,00 | |
| EBIT1,4 | 115,27 | 121,77 | 102,68 | 104,03 | 98,00 | 107,09 | 0,00 | |
| EBIT-Margin5 | 15,46 | 14,54 | 10,01 | 9,21 | 8,25 | 9,28 | 0,00 | |
| Net Profit (Loss)1 | 66,15 | 73,42 | 69,03 | 74,12 | 46,87 | 34,76 | 0,00 | |
| Net-Margin6 | 8,87 | 8,77 | 6,73 | 6,56 | 3,95 | 3,01 | 0,00 | |
| Cashflow1,7 | 110,50 | 149,93 | 165,27 | 145,03 | 179,53 | 128,88 | 0,00 | |
| Earnings per share8 | 1,33 | 1,40 | 1,30 | 1,40 | 0,88 | 0,66 | 1,07 | |
| Dividend per share8 | 0,50 | 0,50 | 0,50 | 0,50 | 1,00 | 0,05 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| CompuGroup Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A28890 | DE000A288904 | SE & Co. KGaA | 1.327,24 Mio € | 04.05.2007 | Halten | 9F299HQG+3H |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 20,25 | 33,87 | 0,60 | 21,50 | 2,06 | 10,30 | 1,15 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,00 | 0,05 | 0,50 | 2,02% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 01.08.2025 | 30.04.2025 | 31.07.2025 | 07.11.2024 | 06.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +2,43% | +6,35% | +13,82% | +13,93% | +37,22% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
